Form 4: Sutro Biopharma Executive Granted Stock Options and Restricted Stock Units

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, received stock options and restricted stock units (RSUs) on March 5, 2024.

Summary

• Venkatesh Srinivasan, the Chief Technical Operations Officer of Sutro Biopharma, was granted stock options and restricted stock units (RSUs) on March 5, 2024.
• The stock options grant consists of 34,000 shares with an exercise price of $4.54.
• These options vest monthly starting April 1, 2024, and will be fully vested by March 1, 2028, contingent upon continued service.
• Additionally, Srinivasan received 25,500 RSUs, which represent the right to receive one share of Sutro Biopharma's common stock per RSU upon settlement.
• The RSUs vest annually, starting March 1, 2025, with complete vesting by March 1, 2028, also subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedules encourage continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted equity.

Industry Context

Equity grants are a common practice in the biopharmaceutical industry to attract, retain, and incentivize key executives. The size and vesting schedule of these grants are generally aligned with industry standards for companies of similar size and stage of development.

Comparison to Industry Standards

• Equity compensation packages for CTOs in biotech companies typically include a mix of stock options and RSUs.
• The vesting schedules (monthly for options, annual for RSUs) are standard practice to ensure long-term commitment.
• Comparable companies like Xencor or MacroGenics also utilize similar equity-based compensation strategies for their executive teams.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates